RNS Number : 6647E
GlaxoSmithKline PLC
19 July 2016
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
|
a)
|
Name
|
Dr P J T Vallance
|
|
b)
|
Position/status
|
President, Pharmaceuticals R&D
|
|
c)
|
Initial notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the transaction
|
Increase in notional interest in Ordinary Shares following the re-investment of dividends
paid to shareholders on 14 July 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
£16.285
|
2,373.465
|
|
£16.285
|
2,433.599
|
|
£16.285
|
3,002.493
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
7,809.558
£16.285
|
|
e)
|
Date of the transaction
|
2016-07-14
|
|
f)
|
Place of the transaction
|
n/a
|
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHVKLFFQDFFBBQ